


# Discover how you can help your patients with chronic pain



The Opioid and Pain Management in Pharmacies Program (OPMPP) research study will explore the benefits and feasibility of offering an opioid and chronic pain medication consultation service between the pharmacist and patient in community pharmacies.

## Why participate?

- Increase your knowledge about offering opioid and chronic pain medication consultations
- Pharmacy will receive professional service fees for completing OPMPP consultations
- Make a positive impact on your patient's health and quality of life

## What will my participation involve?

- Completing a free accredited online continuing education course to boost your knowledge (3 hours)
- Attending an online webinar to understand how to implement the OPMPP intervention in your pharmacy (1 hour)
- Completing up to 3 OPMPP consultations with up to 10 patients per pharmacy (over a period of 6 months)

## Who can participate?

- Part A pharmacists in Ontario
- Working in a community pharmacy that dispenses at least 20 opioid prescriptions per week

**Note:** The pharmacy owner/designated manager must enroll in this study (any additional staff pharmacists will be eligible to enroll after the owner/manager has enrolled and the pharmacy has been selected to participate).

## Interested?

If you are the pharmacy owner/designated manager, click on this [link](https://qfreeaccountssjc1.az1.qualtrics.com/jfe/form/SV_eYdFhYReCDIZRFs) ([https://qfreeaccountssjc1.az1.qualtrics.com/jfe/form/SV\\_eYdFhYReCDIZRFs](https://qfreeaccountssjc1.az1.qualtrics.com/jfe/form/SV_eYdFhYReCDIZRFs)) to learn more about the study and to complete the consent, eligibility and demographics survey.

If you are a staff pharmacist, please wait until your pharmacy owner/designated manager enrolls in the study. They will be responsible for forwarding the consent and information letter to you in order to enroll in this study.

This is part of a research study being conducted by the Ontario Pharmacists Association (OPA) and the University of Waterloo. This study has received ethics clearance through the University of Waterloo Research Ethics Board (REB #45514). For all questions regarding this project, please contact the research team at [opmpp@opatoday.com](mailto:opmpp@opatoday.com).

